阿尔尼拉姆制药公司（Alnylam Pharmaceuticals Inc，股票代码：ALNY）今日盘中股价大跌5.59%，引起市场关注。该公司刚刚发布了截至3月31日的2025年第一季度财报，尽管业绩好于分析师预期，但投资者似乎对公司的整体表现仍持谨慎态度。
根据财报显示，阿尔尼拉姆制药公司第一季度调整后每股亏损为0.44美元，大幅优于分析师预期的每股亏损1.03美元。公司营收同比增长20.2%，达到5.9419亿美元，略高于分析师预期的5.8582亿美元。然而，尽管业绩超预期，公司当季仍录得净亏损5748万美元。
值得注意的是，尽管公司业绩好于预期，但分析师在过去三个月内已经下调了对该公司的盈利预期，降幅约为31.7%。这可能反映出分析师对公司未来盈利能力的担忧。此外，过去30天内有三位分析师对公司的盈利预测进行了负面修正，这也可能影响了投资者的信心。虽然分析师仍然保持对公司股票的"买入"评级，但市场似乎对公司的长期增长前景持更为谨慎的态度，导致股价出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.